Dimerix Stock

Dimerix CROIC

The Cash Return on Invested Capital (CROIC) of Dimerix (DXB.AX) as of Jul 19, 2026 is 289.62 %. In the previous year, Cash Return on Invested Capital (CROIC) was -38.29 % — a change of -856.47% (higher).

CROIC

289.62 %

YoY

-856.47%

Last updated:

Cash Return on Invested Capital (CROIC) of Dimerix is 2026 289.62 % . Cash Return on Invested Capital (CROIC) of Dimerix was 2025 -38.29 % . It decreases by -856.47% higher compared to the previous year.
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Cash Return on Invested Capital (CROIC) of Dimerix is 289.62 % in 2026.

Access this data via the Eulerpool API

Profitability — Dimerix

All Key Metrics — Dimerix